Japan to remain Asia-Pacific's most attractive pharmaceuticals market | Healthcare Asia Magazine
, Japan

Japan to remain Asia-Pacific's most attractive pharmaceuticals market

Despite a pricing regime that limits revenue-generation opportunities for companies.

A large market size, high purchasing power, and a developed regulatory environment are set to maintain Japan’s position as the most attractive pharmaceutical market in the Asia Pacific region and the second-most attractive globally, according to BMI’s Innovative Pharmaceuticals Risk/Reward Index (RRI).

The RRI is a tool that quantifies and ranks a market’s attractiveness to innovative drugmakers by balancing the risks and rewards of launching a product in that market. Aside from Japan, other top-scorers in the index include developed countries with advanced regulatory environments, such as Australia, Canada, the United States, South Korea, and Western Europe.

The index reveals that Japan’s pricing regime is weighing on growth prospects for pharmaceutical companies, with plans currently underway to implement an annual price revision from the existing biennial system. The Ministry of Health, Labour, and Welfare is also seeking to introduce a new rule where prices for medicines listed on the National Health Insurance (NHI) list are reviewed four times a year if the particular medicines saw an expansion in market size due to the addition of new indications, a central strategy for product lifecycle management.

In 2016, NHI-listed drugs saw an average price reduction of 6.8%, severely affecting revenues of multinational pharmaceutical manufacturers. The weakness of the yen is also affecting drug manufacturers, and BMI forecasts a continued weakening of the yen over the long term.

BMI, however, sees pharmaceutical companies bucking these challenges and continuing to launch new products in Japan. The country’s regulatory regime features a well-developed drug approval process, while a strong intellectual property protection system assures patented drugmakers that they will be able to maximize the commercial opportunities for their new products.

Japan also has one of the highest market expenditure in the world, both on a per capita and absolute basis, signifying a preference for and capability to pay for high quality medicines. Its ageing population, with their high demand for chronic disease medication, represents a key demographic for pharmaceutical companies, while a high level of urbanization mean access to advanced healthcare facilities and the greatest pensionable population.

Pemindaian AI terkini meningkatkan diagnosa di Shin Kong Wu Ho-Su Memorial Hospital

Rumah sakit di Taiwan ini menggunakan teknologi endoskop yang dibantu AI untuk mendeteksi polip dan kamera resolusi tinggi untuk telemedis.

KFSHRC Saudi bertumpu pada inovasi untuk mentransformasi layanan kesehatan

Rumah sakit ini mempercepat adopsi teknologi baru untuk memposisikan dirinya sebagai pemimpin global di bidang kedokteran.

Angkor Hospital merencanakan pusat trauma untuk anak-anak

Fasilitas ini akan memiliki ICU, ruang gawat darurat, ruang operasi, dan bangsal bedah.

Bali International Hospital dan HK Asia Medical mendirikan pusat jantung baru

Fasilitas ini akan menawarkan diagnostik, operasi invasif minimal, dan perawatan pasca operasi.

Pasar pencitraan medis Indonesia diproyeksikan tumbuh 6,12% CAGR hingga 2030

Salah satu pendorong utama adalah peningkatan inisiatif yang dipimpin pemerintah.

Rumah Sakit Pusat Kamboja beralih ke adopsi teknologi untuk meningkatkan layanan jantung

Salah satu teknologi kunci mereka adalah mesin ECMO untuk mendukung hidup yang berkepanjangan dalam kondisi kritis.

Ekspor farmasi Indonesia diperkirakan tumbuh 7,7% CAGR hingga 2028

Berkat upaya pemerintah dan aturan investasi baru untuk meningkatkan produksi domestik.

Jepang dan Indonesia tandatangani MoU untuk pelatihan perawat dan pekerja perawatan

Kemitraan ini bertujuan membimbing tenaga kesehatan Indonesia agar memenuhi standar tenaga kerja profesional Jepang.

Pusat gigi nasional Singapura berada di garda terdepan layanan gigi digital

Teknologi pemindaian intraoralnya menggantikan metode pencetakan gigi tradisional.

Inovasi medis global dan solusi berbasis AI menjadi sorotan

Medical Taiwan 2024 menghadirkan 280 peserta dari 10 negara dan mendorong integrasi teknologi dalam layanan kesehatan.